Board of Directors

Greg Studdard

CHIEF EXECUTIVE OFFICER

Greg Studdard brings an expansive network of connections as well as commercial build and new technology launch experience to BioFluidica. He has successfully led several companies and sales teams with breakthrough technologies and services into new Standards of Care in Medicine during his decades long career. He was part of the then largest acquisition in diagnostics in the world when Verinata Health was acquired by Illumina in 2013.

Greg received double majors in Marketing and Management with a minor in Psychology at the University of Virginia and later received his MBA from Chadwick University, a UAB program. He launched national testing at the first prenatal screening lab in the country early in his career with NTD Labs (a Perkin-Elmer/Revvity and later Eurofins company). Later he brought new technology advances in screening and genetic testing to market at GeneCare (Alere at acquisition and now Optum). He brings management, sales, partnering, marketing and managed care experience from his varied experiences, which includes running an Ultrasound company as well as being CCO at a Diabetes company.

Philip Buchanan, PhD, FACMGG

CHAIRMAN OF THE BOARD

Dr. Philip D. Buchanan, PhD., FACMGG is a Medical Geneticist and Clinical Cytogeneticist boarded by the American Board of Medical Genetics and Genomics and the American Board of Medical Specialists. He is an Adjunct Professor of Obstetrics and Gynecology at George Washington University. Dr. Buchanan graduated from North Carolina State University.

Post-doctoral studies were completed at the University of Michigan, Harvard University, and the University of Oregon. He joined the Department of Pediatrics at the University of North Carolina at Chapel Hill in 1970 to direct a new Prenatal Genetic Counseling Clinic and Cytogenetics Laboratory. Dr. Buchanan is a member of several professional societies. He presents and moderates at international meetings, publishes, teaches, and serves as a reviewer for peer-reviewed journals. He has served on college committees and as an NIH, FDA, NIEHS, and EPA Advisor. In 1983, Dr. Buchanan established GeneCare Medical Genetics Center in Chapel Hill. The Center had active international research, clinical laboratories, and teaching programs. Dr. Buchanan served as Executive Vice President for Genetics at Alere. He has helped start and manage multiple private and public companies and foundations. He served as Chairman of the Board for Vestrics, a predictive business analytics corporation. He currently serves as the Chairman of the Board for Voices Together. He serves on the board of the Fetal Medicine Foundation of the USA and of Biofluidica.

Steven A. Soper, PhD

CO-FOUNDER

Dr. Steven A. Soper founded Biofluidica in order to develop new technologies to be used in the medical diagnostic, pathogen detection, and personalized medicine spaces. He is a worldwide recognized pioneer in the development of diagnostic platforms with over 12 years of experience in the CTC research area along with being the author of five patents currently licensed by BioFluidica.

He has over 310 peer-reviewed publications with an h-index of 56. In addition, he has generated over $60M in competitive research funding over his career with most of this funding focused on developing new technologies for in vitro diagnostics. Dr. Soper is currently the Foundation Distinguished Professor in Chemistry and Mechanical Engineering at Kansas University. He is also Director of the Center for BioModular Multi-scale Systems for Precision Medicine, which is focused on developing new tools for the molecular analysis of circulating biomarkers. He also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor.

Michael Stocum

BOARD MEMBER

Michael is an entrepreneurial healthcare and life sciences professional with 20 years of experience leading innovative business initiatives across the pharmaceutical, biotechnology, and clinical laboratory industries by driving strategic vision, business partnerships, and value-added product development.

He has made significant impacts on the development and commercialization of over a dozen products in drug discovery & development, as well as several companion diagnostics, and contributed to the production of a biopharmaceutical. He is the Founder and President of Personalized Medicine Partners LLC. Prior he was the CEO of On-Q-ity and the Director of Business Development at GlaxoSmithKline.